Expanded Newborn Screening and Genomic Sequencing in Latin America and the Resulting Social Justice and Ethical Considerations
Open Access
- 21 January 2021
- journal article
- editorial
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 7 (1), 6
- https://doi.org/10.3390/ijns7010006
Abstract
Newborn screening (NBS) has widely been utilized in developed countries as a cost-effective public health strategy that reduces morbidity and mortality. Developing countries, however, are new to the NBS scene and have their own unique challenges, both in instituting the program as well as effectively acting on the results. NBS offers numerous ethical issues on a global scale, however, here we argue that there are unique ethical issues surrounding the development and expansion of newborn screening in Latin America given its highly heterogenous population. Once a NBS program is effectively instated, ethical considerations continue when pursuing expansion of screening to include further conditions. While Latin America grapples with the ethics of expanded newborn screening (ENBS), some developed countries discuss utility of genomic sequencing technologies in the newborn population. When the ability to detect further pathology is expanded, one must know what to do with this information. As rare diseases are identified either on ENBS or via genome sequencing, access to treatments for these rare diseases can be a real challenge. If we consider newborn screening as a global initiative, then we need more than a deontology approach to analyze these challenges; we need an approach that considers the unique characteristics of each territory and tremendous heterogeneity that exists prior to the implementation of these programs. As genomic technology advances further in the developed world, while some developing countries still lack even basic newborn screening, there is a further widening of the gap in global health disparities. The question is posed as to who has responsibility for these newborns’ lives on an international level. Without an approach towards newborn screening that accounts for the diverse global population, we believe optimal outcomes for newborns and families across the world will not be achieved.Keywords
This publication has 13 references indexed in Scilit:
- Newborn Screening: Beyond the SpotPublished by Springer Science and Business Media LLC ,2017
- Newborn Sequencing in Genomic Medicine and Public HealthPEDIATRICS, 2017
- History of Orphan Drug Regulation—United States and BeyondClinical Pharmacology & Therapeutics, 2016
- Current status of newborn screening worldwide: 2015Seminars in Perinatology, 2015
- Ethical Issues with Newborn Screening in the Genomics EraAnnual Review of Genomics and Human Genetics, 2012
- Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 2 – From screening laboratory results to treatment, follow‐up and quality assuranceJournal of Inherited Metabolic Disease, 2012
- Past, present and future of newborn screening in ChileJournal of Inherited Metabolic Disease, 2010
- Newborn screening in Latin America at the beginning of the 21st centuryJournal of Inherited Metabolic Disease, 2007
- Diagnóstico de fenilquetonuria en ChileRevista chilena de pediatría, 1988
- [Diagnosis of phenylketonuria in Chile].1988